Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Approves List of “Stable Supply Medicines”; Pricing to Become Topic of Discussions
March 30, 2021
- Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
March 29, 2021
- Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
March 29, 2021
- 35.6% of Pfizer Vaccine Recipients Developed Fevers after 2nd Shot, Higher Incidence in Women: MHLW
March 29, 2021
- Nichi-Iko Starting Marketing Operations from March 29
March 29, 2021
- LDP Group to Submit Request for HPV Vaccine Promotion Resumption
March 26, 2021
- Chuikyo to Compile Reimbursement Rule for Therapeutic Apps by Year-End
March 25, 2021
- Chuikyo Members Rail against Generic Manufacturing Scandals
March 25, 2021
- Chuikyo OKs Appraisal Results for Kymriah, Trelegy; Downward Price Tweaks Expected
March 25, 2021
- 6.1% of Hospitals Have Established Formularies: Chuikyo Survey
March 25, 2021
- Nichi-Iko Plant Probed before Lifting of Biz Suspension Order
March 25, 2021
- MHLW Notifies of Guidelines on Use of Registry Data in Regulatory Submissions
March 25, 2021
- Toyama Govt to Probe Repeated Failures to Discover Nichi-Iko’s GMP Violations
March 25, 2021
- Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
- Incidence of Post-Vaccine Anaphylaxis in Japan Comparable with US: MHLW
March 23, 2021
- Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- Govt Disclosing Suspected Vaccine Reactions Less Frequently after Expert Advice: Minister
March 22, 2021
- MHLW Panel Hails Use of Clinical Research Data for Regulatory Submissions, but Wants Requirements to Ensure Safety
March 22, 2021
- MHLW to Set Up Medical Supply Office in April after COVID-19, Antibiotic Shortage
March 19, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…